PT-141
P41
Lyophilized peptide for use under a licensed healthcare provider. Choose single ampule/vial or box of 10. Sourced via Ares Technology Limited (Hong Kong) / Healthtide Biotech manufacturing list dated 7 October 2026. Specification: 10 mg × 10 vials.
- • Prescription / clinician-supervised pathway
- • Same LIRAVEXIN cart and checkout as pen packages
- • Not medical advice — individual suitability is determined by your clinician
Clinical reference (clinician-supervised)
Labeled HSDD in premenopausal women (Vyleesi). Male sexual wellness and off-label clinic uses exist but are not the FDA indication—require separate counseling.
Vyleesi labeled dose: 1.75 mg injected subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity. Max 1 dose/24 h; more than 8 doses/month not recommended.
As needed (PRN), not a daily schedule; monthly dose-count limits apply.
Subcutaneous.
Typical clinical / literature ranges under clinician supervision — not a prescription and not a DIY dosing guide. Individual dosing is determined solely by the treating clinician.
Liravexin USD for this pack (wholesale comparison · source × 3). Item is added to your shared cart for checkout coordination with your clinician pathway.
Or continue to checkout →